BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17217681)

  • 1. [Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure].
    Yu WP; Lou M; Deng B; Song HM; Wang HB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Sep; 34(9):776-80. PubMed ID: 17217681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
    Lee HY; Chung WJ; Jeon HK; Seo HS; Choi DJ; Jeon ES; Kim JJ; Shin JH; Kang SM; Lim SC; Baek SH
    Korean J Intern Med; 2016 Mar; 31(2):277-87. PubMed ID: 26879662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
    Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
    Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy.
    Biolo A; Clausell N; Santos KG; Salvaro R; Ashton-Prolla P; Borges A; Rohde LE
    Am J Cardiol; 2008 Sep; 102(6):726-32. PubMed ID: 18773997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
    Rau T; Düngen HD; Edelmann F; Waagstein F; Lainščak M; Dimković S; Apostolović S; Nešković AN; Haverkamp W; Gelbrich G; Eschenhagen T
    Clin Pharmacol Ther; 2012 Jul; 92(1):21-8. PubMed ID: 22617224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction.
    Iwai C; Akita H; Kanazawa K; Shiga N; Terashima M; Matsuda Y; Takai E; Miyamoto Y; Shimizu M; Kajiya T; Hayashi T; Yokoyama M
    Am Heart J; 2003 Jul; 146(1):106-9. PubMed ID: 12851615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Association of T190C polymorphism of β3 adrenergic receptor gene with response to carvedilol in patients with chronic heart failure].
    Yu H; Wei F; Qian G; Li L; Zhang C; Cheng Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Feb; 32(1):101-4. PubMed ID: 25636111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
    Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
    Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity.
    Bruck H; Leineweber K; Temme T; Weber M; Heusch G; Philipp T; Brodde OE
    J Am Coll Cardiol; 2005 Dec; 46(11):2111-5. PubMed ID: 16325050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol.
    Liu J; Liu ZQ; Tan ZR; Chen XP; Wang LS; Zhou G; Zhou HH
    Clin Pharmacol Ther; 2003 Oct; 74(4):372-9. PubMed ID: 14534524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up.
    Zaugg M; Bestmann L; Wacker J; Lucchinetti E; Boltres A; Schulz C; Hersberger M; Kälin G; Furrer L; Hofer C; Blumenthal S; Müller A; Zollinger A; Spahn DR; Borgeat A
    Anesthesiology; 2007 Jul; 107(1):33-44. PubMed ID: 17585213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibody against beta1-adrenergic receptor and left ventricular remodeling changes in response to metoprolol treatment.
    Miao GB; Liu JC; Liu MB; Wu JL; Zhang G; Chang J; Zhang L
    Eur J Clin Invest; 2006 Sep; 36(9):614-20. PubMed ID: 16919043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of bisoprolol on serum interleukin-6 and tumor necrosis factor-alpha level in patients with congestive heart failure].
    Tang FK; Hua N; Lu H; Xiao J; Tang XZ; Qi Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Dec; 24(12):1177-9. PubMed ID: 19068205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study.
    Zoghi M; Kaya H; Çavuşoğlu Y; Aksakal E; Demir Ş; Yücel C; Mutlu H; Ergene O; Yılmaz MB;
    Turk Kardiyol Dern Ars; 2016 Sep; 44(6):457-65. PubMed ID: 27665326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In patients chronically treated with metoprolol, the demand of inotropic catecholamine support after coronary artery bypass grafting is determined by the Arg389Gly-beta 1-adrenoceptor polymorphism.
    Leineweber K; Bogedain P; Wolf C; Wagner S; Weber M; Jakob HG; Heusch G; Philipp T; Brodde OE
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Jul; 375(5):303-9. PubMed ID: 17541557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimization of use of beta-adrenoblockers in the treatment of chronic heart failure in the outpatient setting].
    Zhubrina ES; Ovchinnikov AG; Seredenina EM; Patrusheva IF; Blankova ZN; Kuz'mina AE; Kheĭmets GI; Ageev FT
    Ter Arkh; 2009; 81(11):35-40. PubMed ID: 20141011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of hyponatremia with plasma renin activity, antidiuretic hormone and brain natriuretic peptide in chronic heart failure].
    Fu L; Ge HL; Li J; Chen GY; Li YS; Xie RS; Fan CY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Sep; 34(9):781-3. PubMed ID: 17217682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity.
    Pereira SB; Velloso MW; Chermont S; Quintão MM; Nunes Abdhala R; Giro C; Oliveira E Alves T; Camacho V; De Fátima Maia Contarato L; Pena FM; Balieiro HM; Garcia ML; Da Nóbrega AC; Ribeiro GS; Mesquita ET
    Mol Med Rep; 2013 Jan; 7(1):259-65. PubMed ID: 23064657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure.
    Bentzen H; Pedersen RS; Nyvad O; Pedersen EB
    Int J Cardiol; 2004 Feb; 93(2-3):121-30. PubMed ID: 14975537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.